Gilead Exercises Option for Assembly Biosciences' HPI Program in $35M Deal

关键事实

1Gilead Sciences licensed Assembly Biosciences' HPI program, triggering a $35 million payment.

2There is potential for up to $330 million in additional milestone payments based on development and regulatory achievements.

3Phase 2 trials for HPI and HDV (ABI-6250) candidates are expected to initiate by the end of 2026.

Gilead Sciences has officially opted into the Helicase-Primase Inhibitor (HPI) program developed by Assembly Biosciences, triggering an immediate $35 million payment. The agreement includes potential future milestone payments of up to $330 million, contingent upon achieving specific development and regulatory goals. This strategic move follows encouraging preclinical and early clinical data, reinforcing the collaborative efforts between the two biotech firms. Clinical progress is expected to continue with Phase 2 trials for both HPI and HDV (ABI-6250) candidates slated to begin by late 2026. For Assembly Biosciences, the deal provides essential non-dilutive capital and validates its research platform through a partnership with a major industry player. While the timeline for clinical results extends into 2026, the partnership underscores a significant long-term commitment to advancing viral disease treatments.

免费注册以访问此内容

创建免费账户